21943-17-9

Basic information

• Product Name: 5-bromo-3-chloropyrazin-2-ol
• Synonyms: 5-bromo-3-chloropyrazin-2-ol;5-bromo-3-chloro-2-hydroxypyrazine;5-Bromo-3-chloropyrazin-2(1H)-one
• CAS NO: 21943-17-9
• Molecular Formula: C₄H₂BrClN₂O
• Molecular Weight: 209.42848
• Mol File: 21943-17-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 5-bromo-3-chloropyrazin-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-3-chloropyrazin-2-ol(21943-17-9)
• EPA Substance Registry System: 5-bromo-3-chloropyrazin-2-ol(21943-17-9)

Safety Data

• Hazardous Substances Data: 21943-17-9(Hazardous Substances Data)

Upstream product

• 21943-13-5 2-amino-5-bromo-3-chloropyrazine 

Downstream Products

• 1410166-31-2 5-bromo-3-(4-phenylpiperidin-1-yl)-1H-pyrazin-2-one 

Relevant articles and documents

INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS

Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.

Design and synthesis of 2(1H)-pyrazinones as inhibitors of protein kinases

Kinase enzymes play a key role in the development and progression of cancer. Inhibitors of deregulated kinases are effective small molecule anticancer drugs. The 2(1H)-pyrazinone heterocycle is a previously unexploited motif that can fulfil the structural requirements for ATP-competitive inhibition of kinases. Rapid solution-phase syntheses of novel 3,5- and 3,6-disubstituted-2(1H)-pyrazinones were developed through selective, sequential substitution of 2,5-dihalo-3-benzyloxypyrazine and 3,5-dihalo-2(1H)-pyrazinone intermediates. Palladium-catalysed cross-couplings and SNAr reactions were used to introduce substituents chosen on the basis of the calculated physicochemical properties of the target pyrazinones. Representative compounds demonstrated good solubility, kinase inhibitory activity and antiproliferative activity in human tumour cells, confirming the suitability of this chemical class as a kinase-focused library.

Design and synthesis of 2(1H)-pyrazinones as inhibitors of protein kinases

Kinase enzymes play a key role in the development and progression of cancer. Inhibitors of deregulated kinases are effective small molecule anticancer drugs. The 2(1H)-pyrazinone heterocycle is a previously unexploited motif that can fulfil the structural requirements for ATP-competitive inhibition of kinases. Rapid solution-phase syntheses of novel 3,5- and 3,6-disubstituted-2(1H)-pyrazinones were developed through selective, sequential substitution of 2,5-dihalo-3-benzyloxypyrazine and 3,5-dihalo-2(1H)-pyrazinone intermediates. Palladium-catalysed cross-couplings and SNAr reactions were used to introduce substituents chosen on the basis of the calculated physicochemical properties of the target pyrazinones. Representative compounds demonstrated good solubility, kinase inhibitory activity and antiproliferative activity in human tumour cells, confirming the suitability of this chemical class as a kinase-focused library.